GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 percent ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...